Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Other financing activities (2016 - 2019)

Sunshine Biopharma's Other financing activities history spans 7 years, with the latest figure at $7590.0 for Q4 2019.

  • For Q4 2019, Other financing activities fell 98.92% year-over-year to $7590.0; the TTM value through Dec 2020 reached $7590.0, changed N/A, while the annual FY2018 figure was $676100.0, 58.19% up from the prior year.
  • Other financing activities reached $7590.0 in Q4 2019 per SBFM's latest filing, up from -$7590.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $705568.0 in Q4 2018 to a low of -$411566.0 in Q2 2018.
  • Average Other financing activities over 4 years is $138907.7, with a median of $64000.0 recorded in 2017.
  • The largest YoY upside for Other financing activities was 3261.81% in 2018 against a maximum downside of 743.07% in 2018.
  • A 4-year view of Other financing activities shows it stood at $282800.0 in 2016, then crashed by 120.05% to -$56700.0 in 2017, then skyrocketed by 1344.39% to $705568.0 in 2018, then crashed by 98.92% to $7590.0 in 2019.
  • Per Business Quant, the three most recent readings for SBFM's Other financing activities are $7590.0 (Q4 2019), -$7590.0 (Q2 2019), and $705568.0 (Q4 2018).